Cited by 1Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography

Open access
Le, Hannah, Raymond, Roger, Vasdev, Neil, Ni, Ruiqing, Zheng, Chao·2025·Alzheimer's & Dementia

Abstract

Abstract Background Synaptic vesicle glycoprotein 2A (SV2A), a biomarker for synaptic density; purinergic receptor P2Y12R, a marker of microglia activation; and hyperphosphorylated tau have been extensively studied in Alzheimer's disease (AD), with growing interest in how these factors affect each other and enhance their impact. In vitro autoradiography (ARG) studies were carried out to evaluate the expression and distribution of P2Y12R, SV2A, and tau using [ 3 H]PSB‐0413, [ 3 H]UCB‐J and [ 18 F]MK‐6240 respectively, in postmortem brain tissues from AD versus cognitively normal health controls (CN). Binding correlation analysis was also conducted. Method [ 18 F]MK‐6240 was synthesized in‐house, whereas [ 3 H]PSB‐0413 and [ 3 H]UCB‐J were custom synthesized (Novandi AB, Sweden). Thin section ARG binding assays were performed on post‐mortem hippocampal/BA28 and entorhinal cortex tissues from CN ( n = 3) and AD patients ( n = 5). Radiotracer binding was quantified using digital ARG and non‐specific binding was determined through homologous blockage with 10 µM of Suramin, Levetiracetam, and cold MK‐6240, known ligands for P2Y12R, SV2A and tau, respectively. Result [ 3 H]PSB‐0413 autoradiography revealed significant decreased binding in the subiculum (SUB) and entorhinal cortex (EC) of AD compared to CN. [ 3 H]UCB‐J ARG showed significant decrease in the dentate gyrus (DG), CA1, and EC of AD compared to CN. [ 18 F]MK‐6240 showed strong binding to tau aggregates throughout the hippocampus of AD, with minimal off‐target binding in CN, with a significant increased in binding observed in AD patients in CA1 and SUB compared to CN. When comparing binding in subregions in AD patients, [ 3 H]UCB‐J (R 2 = 0.57, p < 0.0001) and [ 3 H]MK‐6240 (R 2 = 0.57, p < 0.0001) have a significant association with [ 3 H]PSB‐0413. The two tracers also share a significant correlation themselves (R 2 = 0.48, p = 0.0002). Conclusion This study demonstrates that SV2A levels decrease while tau accumulations increase in AD brains with [ 3 H]UCB‐J and [ 18 F]MK‐6420 respectively, and our data is consistent with in vivo human PET imaging studies of SV2A and tau. We also showed that P2Y12R is decreased in AD brains with [ 3 H]PSB‐0413. Positive correlation between regional binding of the three tracers was shown in AD patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz70856_102328

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SV2A levels eventually decrease in correlation with tau accumulation and glymphatic impairment in late-stage Alzheimer's.

    “While SV2A levels eventually decrease in correlation with tau accumulation and glymphatic impairment in late-stage Alzheimer’s, certain regions may show a compensatory increase in SV2A binding during early disease stages [93,94,95].”

    From Molecular Physiology of the Neuronal Synapse (2026) · cites this paper as [95]

    The Conclusion reports decreased SV2A and increased tau accumulation in AD brains, supporting that part of the claim. The Methods and Results describe postmortem AD-versus-control tissue, not a late-stage trajectory, and do not assess glymphatic impairment. The reported correlation between SV2A and tau tracer binding within AD subregions is positive, so it should not be described as a demonstrated correlation between falling SV2A and rising tau. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Certain regions may show a compensatory increase in SV2A binding during early disease stages.

    “While SV2A levels eventually decrease in correlation with tau accumulation and glymphatic impairment in late-stage Alzheimer’s, certain regions may show a compensatory increase in SV2A binding during early disease stages [93,94,95].”

    From Molecular Physiology of the Neuronal Synapse (2026) · cites this paper as [95]

    The Results report decreased SV2A-tracer binding in the dentate gyrus, CA1, and entorhinal cortex of AD brains compared with controls. The Methods and Conclusion do not distinguish early from later disease stages or describe a compensatory increase; searches for those terms found no supporting passage. The reported decreases do not rule out a possible increase at an unexamined early stage. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cited by

Sorted by citations

  • Molecular Physiology of the Neuronal Synapse

    Ramírez-Expósito, M. J., Cueto-Ureña, C., & Martínez-Martos, J. M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010088 · Cited by 6 · see citing works

    “While SV2A levels eventually decrease in correlation with tau accumulation and glymphatic impairment in late-stage Alzheimer’s, certain regions may show a compensatory increase in SV2A binding during early disease stages [93–95].”

Authors
Le, H., Raymond, R., Vasdev, N., Ni, R., & Zheng, C.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University of Zurich (CH)
Corresponding author
Le, Hannah
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2025-12
Volume
21
Issue
S2
Pages
e102328-e102328
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W7117309708
Cited by
1
References
0
Citations by year
2026: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, P2Y12 receptor
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Autoradiography, Brain, Female, Humans, Isoquinolines, Male, Membrane Glycoproteins, Nerve Tissue Proteins, Biomarkers, tau Proteins, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review